(RELX) Relx - Overview
Stock: Analytics, Data, Legal, Scientific, Exhibitions
Dividends
| Dividend Yield | 1.59% |
| Yield on Cost 5y | 3.60% |
| Yield CAGR 5y | 5.28% |
| Payout Consistency | 90.3% |
| Payout Ratio | 1.6% |
| Risk 5d forecast | |
|---|---|
| Volatility | 55.9% |
| Relative Tail Risk | 2.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.93 |
| Alpha | -50.99 |
| Character TTM | |
|---|---|
| Beta | 0.492 |
| Beta Downside | 0.320 |
| Drawdowns 3y | |
|---|---|
| Max DD | 46.93% |
| CAGR/Max DD | 0.05 |
Description: RELX Relx January 28, 2026
RELX PLC (NYSE: RELX) is a London-based information-services group that delivers data-driven analytics and decision tools to professional customers across four business segments: Risk, Scientific, Technical & Medical (STM), Legal, and Exhibitions. The company evolved from Reed Elsevier and rebranded in 2015, leveraging a legacy of over 120 years in publishing and data-intelligence.
In FY 2025 the firm reported total revenue of £9.8 billion, up 5 % YoY, with the Risk segment contributing the largest share (≈ £4.2 bn) and posting a 7 % organic growth rate driven by heightened demand for cyber-risk and regulatory-compliance solutions. The STM segment grew 4 % on the back of expanding subscriptions to life-science databases, while the Legal segment saw a 3 % rise, reflecting continued investment in AI-assisted contract analytics. Exhibitions, still in a recovery phase post-pandemic, posted a modest 2 % increase as hybrid event models gain traction. Across the group, operating margin improved to 31 % as cost-efficiency programs offset inflationary pressures.
Key macro drivers include sustained corporate spending on risk-management software (global market projected to reach $45 bn by 2027) and accelerating digital transformation in the life-science and legal sectors, both of which underpin RELX’s growth outlook. For a deeper, data-rich assessment of RELX’s valuation dynamics, a quick look at ValueRay’s analyst dashboards can surface the most current forward-looking metrics.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 3.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.35 > 0.02 and ΔFCF/TA 9.14 > 1.0 |
| NWC/Revenue: -16.14% < 20% (prev -39.34%; Δ 23.20% < -1%) |
| CFO/TA 0.37 > 3% & CFO 5.31b > Net Income 3.82b |
| Net Debt (7.32b) to EBITDA (5.89b): 1.24 < 3 |
| Current Ratio: 0.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.84b) vs 12m ago -3.46% < -2% |
| Gross Margin: 64.67% > 18% (prev 0.61%; Δ 6406 % > 0.5%) |
| Asset Turnover: 146.4% > 50% (prev 114.4%; Δ 32.01% > 0%) |
| Interest Coverage Ratio: 6.21 > 6 (EBITDA TTM 5.89b / Interest Expense TTM 671.0m) |
Altman Z'' 1.41
| A: -0.21 (Total Current Assets 2.73b - Total Current Liabilities 5.77b) / Total Assets 14.32b |
| B: 0.13 (Retained Earnings 1.89b / Total Assets 14.32b) |
| C: 0.32 (EBIT TTM 4.16b / Avg Total Assets 12.87b) |
| D: 0.18 (Book Value of Equity 2.22b / Total Liabilities 12.13b) |
| Altman-Z'' Score: 1.41 = BB |
Beneish M -3.17
| DSRI: 0.75 (Receivables 2.16b/1.99b, Revenue 18.84b/13.05b) |
| GMI: 0.94 (GM 64.67% / 61.09%) |
| AQI: 0.83 (AQ_t 0.80 / AQ_t-1 0.97) |
| SGI: 1.44 (Revenue 18.84b / 13.05b) |
| TATA: -0.10 (NI 3.82b - CFO 5.31b) / TA 14.32b) |
| Beneish M-Score: -3.17 (Cap -4..+1) = AA |
What is the price of RELX shares?
Over the past week, the price has changed by -17.93%, over one month by -29.51%, over three months by -32.29% and over the past year by -40.78%.
Is RELX a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RELX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 54 | 83.6% |
| Analysts Target Price | 54 | 83.6% |
| ValueRay Target Price | 28.9 | -1.5% |
RELX Fundamental Data Overview February 05, 2026
P/E Trailing = 21.6383
P/E Forward = 15.7233
P/S = 5.7988
P/B = 18.5456
P/EG = 1.4826
Revenue TTM = 18.84b GBP
EBIT TTM = 4.16b GBP
EBITDA TTM = 5.89b GBP
Long Term Debt = 5.53b GBP (from longTermDebt, last quarter)
Short Term Debt = 1.94b GBP (from shortTermDebt, last quarter)
Debt = 7.54b GBP (from shortLongTermDebtTotal, last quarter)
Net Debt = 7.32b GBP (from netDebt column, last quarter)
Enterprise Value = 47.83b GBP (40.51b + Debt 7.54b - CCE 211.0m)
Interest Coverage Ratio = 6.21 (Ebit TTM 4.16b / Interest Expense TTM 671.0m)
EV/FCF = 9.51x (Enterprise Value 47.83b / FCF TTM 5.03b)
FCF Yield = 10.51% (FCF TTM 5.03b / Enterprise Value 47.83b)
FCF Margin = 26.69% (FCF TTM 5.03b / Revenue TTM 18.84b)
Net Margin = 20.26% (Net Income TTM 3.82b / Revenue TTM 18.84b)
Gross Margin = 64.67% ((Revenue TTM 18.84b - Cost of Revenue TTM 6.66b) / Revenue TTM)
Gross Margin QoQ = 66.25% (prev 64.72%)
Tobins Q-Ratio = 3.34 (Enterprise Value 47.83b / Total Assets 14.32b)
Interest Expense / Debt = 2.91% (Interest Expense 219.0m / Debt 7.54b)
Taxrate = 23.69% (304.0m / 1.28b)
NOPAT = 3.18b (EBIT 4.16b * (1 - 23.69%))
Current Ratio = 0.47 (Total Current Assets 2.73b / Total Current Liabilities 5.77b)
Debt / Equity = 3.46 (Debt 7.54b / totalStockholderEquity, last quarter 2.18b)
Debt / EBITDA = 1.24 (Net Debt 7.32b / EBITDA 5.89b)
Debt / FCF = 1.46 (Net Debt 7.32b / FCF TTM 5.03b)
Total Stockholder Equity = 3.08b (last 4 quarters mean from totalStockholderEquity)
RoA = 29.66% (Net Income 3.82b / Total Assets 14.32b)
RoE = 123.8% (Net Income TTM 3.82b / Total Stockholder Equity 3.08b)
RoCE = 48.35% (EBIT 4.16b / Capital Employed (Equity 3.08b + L.T.Debt 5.53b))
RoIC = 32.25% (NOPAT 3.18b / Invested Capital 9.85b)
WACC = 6.87% (E(40.51b)/V(48.04b) * Re(7.73%) + D(7.54b)/V(48.04b) * Rd(2.91%) * (1-Tc(0.24)))
Discount Rate = 7.73% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -81.65 | Cagr: -1.39%
[DCF Debug] Terminal Value 85.05% ; FCFF base≈4.20b ; Y1≈5.18b ; Y5≈8.83b
Fair Price DCF = 102.6 (EV 193.21b - Net Debt 7.32b = Equity 185.88b / Shares 1.81b; r=6.87% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 38.20 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.77 | Revenue CAGR: 12.89% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=1.92 | Chg30d=+0.027 | Revisions Net=+2 | Growth EPS=+10.3% | Growth Revenue=+6.7%